Kymab, is included in the 2020 Sunday Times Sage Tech Track 100, which ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years.
Cambridge, UK; 7 September 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, has been included in the 2020 Sunday Times Sage Tech Track 100. The results were published, Sunday 6 September, 2020, with The Sunday Times Business section, on their tablet edition, and on the Fast Track website.
The Sunday Times Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years.
Kymab featured in 2015 in The Sunday Times Tech Track Ones to Watch, recognising Kymab’s potential for rapid future growth and increasing international presence. At the end of 2017, Kymab was recognised as one of the 50 fastest-growing technology companies in the UK in the Deloitte UK Technology Fast 50, while in 2018, Kymab was included as one of nine 'top European biotechs to watch' by Labiotech.eu.
Notes to Editors
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody development platforms available.
Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently.
For more information on Kymab please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.